Bruton Tyrosine Kinase (BTK) inhibitor

News

An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.